

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

DEXMOPET 0.5 mg/ml solution for injection for dogs and cats [BE, BG, CY, CZ, DE, ES, IE, PL, PT, SK]

DEXMOPET solution for injection for dogs and cats [FR]

DEXMOPET-vet 0.5 mg/ml solution for injection for dogs and cats [DK, NO, SE]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Dexmedetomidine 0.42 mg
(equivalent to 0.5 mg of dexmedetomidine hydrochloride)

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Methyl parahydroxybenzoate (E 218)	1.60 mg
Propyl parahydroxybenzoate (E 216)	0.20 mg
Sodium chloride	
Solvent:	
Water for injections	

Clear, colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs and cats.

3.2 Indications for use for each target species

Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.

Deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures.

Premedication in dogs and cats before induction and maintenance of general anaesthesia.

3.3 Contraindications

Do not use in animals with cardiovascular disorders, severe systemic disease or impaired liver or kidney function.

Do not use in animals with mechanical disturbances or the gastrointestinal tract (torsio ventriculi, incarcerations, oesophageal obstructions).

Do not use in pregnant animals.

Do not use in animals with diabetes mellitus.

Do not use in cases of state of shock, emaciation or serious debilitation.

Do not use concomitantly with sympathomimetic amines.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals with ocular problems where an increase in intraocular pressure would be detrimental.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.

It is recommended that animals are fasted for 12 hours prior to the veterinary medicinal product administration. Water may be given.

After treatment, the animal should not be given water or food before it is able to swallow.

The eyes should be protected by a suitable lubricant.

To be used with precaution in elderly animals.

Nervous, aggressive or excited animals should be given the possibility to calm down before initiation of treatment.

Frequent and regular monitoring of respiratory and cardiac function should be performed. Pulse oximetry may be useful but is not essential for adequate monitoring. Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats. It is also advisable to have oxygen readily available, should hypoxaemia be detected or suspected.

Sick and debilitated dogs and cats should only be premedicated with dexmedetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.

Use of dexmedetomidine as a premedicant in dogs and cats significantly reduces the amount of induction drug required for induction of anaesthesia. Attention should be given during the administration of intravenous induction drugs to effect. Volatile anaesthetic requirements for maintenance anaesthesia are also reduced.

The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

As sedation and changes in blood pressure may occur DO NOT DRIVE in case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician.

In case of contact with skin, wash the exposed skin immediately after exposure with large amounts of water. Remove contaminated clothes that are in direct contact with skin.

In case of accidental contact of the veterinary medicinal product with eyes, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.

Avoid skin, eye or mucosal contact.

As uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure if pregnant women handle the veterinary medicinal product, special caution should be observed not to self-inject.

People with known hypersensitivity to dexmedetomidine or any of the excipients should administer the veterinary medicinal product with caution.

Advice to the physician:

Dexmedetomidine is an α_2 -adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and

haemodynamic symptoms should be treated symptomatically. The specific α_2 -adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Very common (> 1 animal / 10 animals treated):	Bradycardia ^{1,5} Cyanotic mucous membranes ² , Pale mucous membranes ²
Common (1 to 10 animals / 100 animals treated):	Arrhythmia ^{6,8,9}
Rare (1 to 10 animals / 10 000 animals treated):	Pulmonary oedema
Undetermined frequency (cannot be estimated from the available data):	Excitation ¹ Heart block ¹ , Premature ventricular contractions ¹ , High blood pressure ³ , Low blood pressure ³ , Hypersalivation ¹ , Retching ¹ , Vomiting ^{1,4} Muscle tremor ¹ , Twitching ¹ , Paddling ¹ , Sedation prolonged ¹ Bradypnoea ^{1,5} , Tachypnoea ^{1,5} , Irregular breathing ^{1,7} , Decreased pulse oxygenation ¹ , Erythema ¹ Decreased body temperature Urination ¹

¹ When dexmedetomidine and butorphanol are used concomitantly.

² Due to peripheral vasoconstriction and venous desaturation in the presence of normal arterial oxygenation.

³ Blood pressure will increase initially and then return to normal or below normal.

⁴ May occur 5–10 minutes after injection. Some dogs may also vomit at the time of recovery.

⁵ When dexmedetomidine is used as a premedicant.

⁶ When dexmedetomidine and butorphanol are used concomitantly in dogs, brady- and tachyarrhythmias have been reported. These may include profound sinus bradycardia, 1st and 2nd degree AV block, sinus arrest or pause, as well as atrial, supraventricular and ventricular premature complexes.

⁷ 20–30 sec apnea followed by rapid breaths.

⁸ When dexmedetomidine is used as a premedicant brady- and tachyarrhythmias have been reported and include profound sinus bradycardia, 1st and 2nd degree AV block and sinus arrest. Supraventricular and ventricular premature complexes, sinus pause, and 3rd degree AV block may be observed in rare cases.

⁹ Supraventricular and nodal arrhythmia when dexmedetomidine and butorphanol are used concomitantly.

Cats:

Very common (> 1 animal / 10 animals treated):	Bradycardia ¹ , Arrhythmia ⁶ Heart block ^{1,2} Vomiting ^{1,2,3} Pale mucous membranes ^{1,4} , Cyanotic mucous membranes ⁴
---	--

Common (1 to 10 animals / 100 animals treated):	Retching ¹ Decreased pulse oxygenation ^{2,7} Hypothermia ²
Uncommon (1 to 10 animals / 1 000 animals treated):	Apnoea ²
Rare (1 to 10 animals / 10 000 animals treated):	Pulmonary oedema
Undetermined frequency (cannot be estimated from the available data):	Extrasystole ² , High blood pressure ⁵ , Low blood pressure ⁵ Corneal opacity Muscle tremor, Decreased body temperature ¹ Bradypnoea ² , Decreased respiratory rate, Hypoventilation ² , Irregular breathing ² Agitation ²

¹ When dexmedetomidine is used as a premedicant.

² When dexmedetomidine and ketamine are used sequentially.

³ May occur 5–10 minutes after injection. Some cats may also vomit at the time of recovery.

⁴ Due to peripheral vasoconstriction and venous desaturation in the presence of normal arterial oxygenation.

⁵ Blood pressure will increase initially and then return to normal or below normal.

⁶ Intramuscular dosing at 40 micrograms/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.

⁷ Especially within the 15 first minutes into dexmedetomidine-ketamine anaesthesia.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of dexmedetomidine has not been established during pregnancy and lactation in the target species.

Pregnancy and lactation:

The use of the veterinary medicinal product during pregnancy and lactation is not recommended.

Fertility:

The safety of dexmedetomidine has not been established in males intended for breeding.

3.8 Interaction with other medicinal products and other forms of interaction

The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made. Anticholinergics should be used with caution with dexmedetomidine.

Administration of atipamezole after dexmedetomidine rapidly reverses the effects and thus shortens the recovery period. Within 15 minutes dogs and cats are normally awake and standing.

Cats: After administration of 40 micrograms dexmedetomidine/kg bw intramuscularly concurrently with 5 mg ketamine/kg bw to cats, the maximum concentration of dexmedetomidine increased twofold but there was no effect on Tmax. The mean half-life of elimination of dexmedetomidine increased to 1.6 h and the total exposure (AUC) increased by 50%.

A dose of 10 mg ketamine/kg used concurrently with 40 micrograms dexmedetomidine/kg may cause tachycardia.

3.9 Administration route and dosage

- Dogs: intravenous or intramuscular use
- Cats: intramuscular use

The veterinary medicinal product is not intended for repeated injections.

Dexmedetomidine, butorphanol and/or ketamine can be mixed in the same syringe as they have been shown to be pharmaceutically compatible.

The stopper must not be punctured more than 25 times.

Dosage: the following doses are recommended:

Dogs:

Dexmedetomidine doses are based on body surface area:

Intravenously: up to 375 micrograms/square metre body surface area

Intramuscularly: up to 500 micrograms/square metre body surface area

When administering in conjunction with butorphanol (0.1 mg/kg bw) for deep sedation and analgesia, the intramuscular dose of dexmedetomidine is 300 micrograms/square metre body surface area. The premedication dose of dexmedetomidine is 125 – 375 micrograms/square metre body surface area, administered 20 minutes prior to induction for procedures requiring anaesthesia. The dose should be adjusted to the type of surgery, length of procedure and patient temperament.

Concomitant use of dexmedetomidine and butorphanol produces sedative and analgesic effects beginning no later than 15 minutes. The peak sedative and analgesic effects are reached within 30 minutes after administration. Sedation lasts for at least 120 minutes post administration and analgesia lasts for at least 90 minutes. Spontaneous recovery occurs within 3 hours.

Premedication with dexmedetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. In a clinical study, the requirement for propofol and thiopental was reduced by 30% and 60% respectively. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect. In a clinical study, dexmedetomidine contributed to postoperative analgesia for 0.5 – 4 hours. However, this duration is dependent on a number of variables and further analgesia should be administered in accordance with clinical judgement.

The corresponding doses based on body weight are presented in the following tables. Use of an appropriately graduated syringe is recommended to ensure accurate dosing when administering small volumes.

Dog Weight (kg)	Dexmedetomidine 125 mcg/m² (mcg/kg bw)	Dexmedetomidine 375 mcg/m² (mcg/kg bw)	Dexmedetomidine 500 mcg/m² (mcg/kg bw)
2-3	9.4	0.04	28.1
3-4	8.3	0.05	25
4-5	7.7	0.07	23

5-10	6.5	0.1	19.6	0.29	25	0.4
10-13	5.6	0.13	16.8	0.38	23	0.5
13-15	5.2	0.15	15.7	0.44	21	0.6
15-20	4.9	0.17	14.6	0.51	20	0.7
20-25	4.5	0.2	13.4	0.6	18	0.8
25-30	4.2	0.23	12.6	0.69	17	0.9
30-33	4	0.25	12	0.75	16	1.0
33-37	3.9	0.27	11.6	0.81	15	1.1
37-45	3.7	0.3	11	0.9	14.5	1.2
45-50	3.5	0.33	10.5	0.99	14	1.3
50-55	3.4	0.35	10.1	1.06	13.5	1.4
55-60	3.3	0.38	9.8	1.13	13	1.5
60-65	3.2	0.4	9.5	1.19	12.8	1.6
65-70	3.1	0.42	9.3	1.26	12.5	1.7
70-80	3	0.45	9	1.35	12.3	1.8
>80	2.9	0.47	8.7	1.42	12	1.9

For deep sedation and analgesia with butorphanol

Dog Weight (kg)	Dexmedetomidine 300 mcg/m ² intramuscularly (mcg/kg bw)	(ml)
2-3	24	0.12
3-4	23	0.16
4-5	22.2	0.2
5-10	16.7	0.25
10-13	13	0.3
13-15	12.5	0.35
15-20	11.4	0.4
20-25	11.1	0.5
25-30	10	0.55
30-33	9.5	0.6
33-37	9.3	0.65
37-45	8.5	0.7
45-50	8.4	0.8
50-55	8.1	0.85
55-60	7.8	0.9
60-65	7.6	0.95
65-70	7.4	1
70-80	7.3	1.1
>80	7	1.2

Cats:

The dosage for cats is 40 mcg dexmedetomidine hydrochloride/kg bw equal to a dose volume 0.08 ml of the veterinary medicinal product/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.

When dexmedetomidine is used for premedication in cats, the same dose is used. Premedication with dexmedetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. In a clinical study, the requirement for propofol was reduced by 50%. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect.

Anaesthesia can be induced 10 minutes after premedication by intramuscular administration of a target dose of 5 mg ketamine/kg bw or by intravenous administration of propofol to effect. Dosing for cats is presented in the following table.

Cat Weight (kg)	Dexmedetomidine 40 mcg/kg intramuscularly (mcg/kg bw) (ml)
1-2	40 0.1
2-3	40 0.2
3-4	40 0.3
4-6	40 0.4
6-7	40 0.5
7-8	40 0.6
8-10	40 0.7

The expected sedative and analgesic effects are reached within 15 minutes after administration and are maintained up to 60 minutes after administration. Sedation may be reversed with atipamezole. Atipamezole should not be administered prior to 30 minutes following ketamine administration.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Dogs:

In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area). The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of the veterinary medicinal product that was given to the dog, regardless of route of administration of the veterinary medicinal product.

Cats:

In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose dexmedetomidine in micrograms/kg bw.

After concurrent exposure to a triple (3X) overdose of dexmedetomidine and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine. At high serum concentrations of dexmedetomidine sedation is not increased although the level of analgesia does increase with further dose increases. The dose volume of atipamezole at the concentration of 5 mg/ml equals one-half the volume of the veterinary medicinal product that was given to the cat.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

3.12 Withdrawal periods

Not applicable

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QN05CM18.

4.2 Pharmacodynamics

This veterinary medicinal product contains dexmedetomidine as the active substance, which produces sedation and analgesia in dogs and cats. The duration and depth of the sedation and analgesia are dose-dependent. At maximal effect, the animal is relaxed, recumbent and does not respond to external stimulus.

Dexmedetomidine is a potent and selective α_2 -adrenoceptor agonist that inhibits the release of noradrenaline from noradrenergic neurons. Sympathetic neurotransmission is prevented and the level of consciousness decreases. Reduced heart rate and temporary AV-block can be seen after administration of dexmedetomidine. Blood pressure decreases to normal or below normal levels after an initial increase. Respiration rate can occasionally decrease. Dexmedetomidine also induces a number of other α_2 -adrenoceptor mediated effects, which include piloerection, depression of motor and secretory functions of the gastrointestinal tract, diuresis and hyperglycaemia.

A slight decrease in temperature may be observed.

4.3 Pharmacokinetics

As a lipophilic compound, dexmedetomidine is well absorbed after intramuscular administration. Dexmedetomidine is also rapidly distributed in the body and penetrates the blood-brain barrier readily. According to studies in rats, the maximum concentration in the central nervous system is several times that of the corresponding concentration in plasma. In the circulation, dexmedetomidine is largely bound to plasma proteins (>90%).

Dogs: After an intramuscular dose of 50 micrograms/kg a maximum concentration in plasma of about 12 ng/ml is reached after 0.6 hours. The bioavailability of dexmedetomidine is 60% and the apparent volume of distribution (Vd) is 0.9 l/kg. The elimination half-life ($t_{1/2}$) is 40-50 minutes.

Major biotransformations in the dog include hydroxylation, glucuronic acid conjugation and N-methylation in the liver. All known metabolites lack pharmacological activity. Metabolites are excreted mainly in the urine and to a lesser extent in the faeces. Dexmedetomidine has a high clearance and its elimination depends on the hepatic blood flow. A prolonged elimination half-life is therefore expected with overdoses or when dexmedetomidine is coadministered with other substances, which affect hepatic circulation.

Cats: The maximum plasma concentration is reached about 0.24 h after intramuscular administration. After a 40 micrograms/kg bw intramuscular dose the Cmax is 17 ng/ml. The apparent volume of distribution (Vd) is 2.2 l/kg and the elimination half-life ($t_{1/2}$) is one hour.

Biotransformations in the cat occur by hydroxylation in the liver. Metabolites are excreted mainly in the urine (51% of the dose), and to a lesser extent in the faeces. As in dogs dexmedetomidine has a high clearance in cats and its elimination depends on the hepatic blood flow. A prolonged elimination half-life is therefore expected with overdoses or when dexmedetomidine is coadministered with other substances, which affect hepatic circulation.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products, with the following exception: Dexmedetomidine is compatible with butorphanol and ketamine in the same syringe at least for two hours.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.
Shelf life after first opening the immediate packaging: 28 days.

5.3. Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4. Nature and composition of immediate packaging

Cardboard box with one clear glass vial (type I) of 10 ml, closed with a bromobutyl rubber stopper and aluminium cap with a polypropylene “flip-off” seal.

Pack sizes:

Cardboard box with 1 vial of 10 ml

5.5. Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

VETPHARMA ANIMAL HEALTH, S.L.

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: {dd/mm/yyyy}

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription. Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**BOX****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

DEXMOPET 0.5 mg/ml solution for injection BE, BG, CY, CZ, DE, ES, IE, PL, PT, SK]

DEXMOPET solution for injection [FR]

DEXMOPET-vet 0.5 mg/ml solution for injection [DK, NO, SE]

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml contains 0.5 mg dexmedetomidine hydrochloride equivalent to 0.42 mg dexmedetomidine.

3. PACKAGE SIZE

10 ml

4. TARGET SPECIES

Dogs and cats.

5. INDICATIONS

[To be included only for medicinal products not subject to medical prescription.]

6. ROUTES OF ADMINISTRATION

Dogs: Intravenous or Intramuscular use.

Cats: Intramuscular use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp: {mm/yyyy}

Once opened use by 28 days.

9. SPECIAL STORAGE PRECAUTIONS**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREAT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VETPHARMA ANIMAL HEALTH, S.L.

14. MARKETING AUTHORISATION NUMBERS**15. BATCH NUMBER**

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

DEXMOPET [BE, BG, CY, CZ, DE, ES, IE, PL, PT, SK]

DEXMOPET [FR]

DEXMOPET-vet [DK, NO, SE]

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE

0.5 mg/ml dexmedetomidine hydrochloride.

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use by...

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

DEXMOPET 0.5 mg/ml solution for injection for dogs and cats [BE, BG, CY, CZ, DE, ES, IE, PL, PT, SK]

DEXMOPET solution for injection for dogs and cats [FR]

DEXMOPET-vet 0.5 mg/ml solution for injection for dogs and cats [DK, NO, SE]

2. Composition

Each ml contains:

Active substance:

Dexmedetomidine 0.42 mg
(equivalent to 0.5 mg of dexmedetomidine hydrochloride)

Excipients:

Methyl parahydroxybenzoate (E 218) 1.60 mg
Propyl parahydroxybenzoate (E 216) 0.20 mg

Clear, colourless solution.

3. Target species

Dogs, cats.

4. Indications for use

Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.

Deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures.

Premedication in dogs and cats before induction and maintenance of general anaesthesia.

5. Contraindications

Do not use in animals with cardiovascular disorders, severe systemic disease or impaired liver or kidney function.

Do not use in animals with mechanical disturbances or the gastrointestinal tract (torsio ventriculi, incarcerations, oesophageal obstructions).

Do not use in pregnant animals (see also "Special Warnings")

Do not use in animals with diabetes mellitus.

Do not use in cases of state of shock, emaciation or serious debilitation.

Do not use concomitantly with sympathomimetic amines.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals with ocular problems where an increase in intraocular pressure would be detrimental.

6. Special warnings

Special warnings:

None.

Special precautions for safe use in the target species:

Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.

It is recommended that animals are fasted for 12 hours prior to the veterinary medicinal product administration. Water may be given.

After treatment, the animal should not be given water or food before it is able to swallow.

The eyes should be protected by a suitable lubricant.

To be used with precaution in elderly animals.

Nervous, aggressive or excited animals should be given the possibility to calm down before initiation of treatment.

Frequent and regular monitoring of respiratory and cardiac function should be performed. Pulse oximetry may be useful but is not essential for adequate monitoring. Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats. It is also advisable to have oxygen readily available, should hypoxaemia be detected or suspected.

Sick and debilitated dogs and cats should only be premedicated with dexmedetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.

Use of dexmedetomidine as a premedicant in dogs and cats significantly reduces the amount of induction drug required for induction of anaesthesia. Attention should be given during the administration of intravenous induction drugs to effect. Volatile anaesthetic requirements for maintenance anaesthesia are also reduced.

The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

As sedation and changes in blood pressure may occur DO NOT DRIVE in case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician.

In case of contact with skin, wash the exposed skin immediately after exposure with large amounts of water. Remove contaminated clothes that are in direct contact with skin.

In case of accidental contact of the veterinary medicinal product with eyes, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.
Avoid skin, eye or mucosal contact.

As uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure if pregnant women handle the veterinary medicinal product, special caution should be observed not to self-inject.

People with known hypersensitivity to dexmedetomidine or any of the excipients should administer the veterinary medicinal product with caution.

Advice to the physician:

Dexmedetomidine is an α_2 -adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically. The specific α_2 -adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

The safety of dexmedetomidine has not been established during pregnancy and lactation in the target species.

The use of the veterinary medicinal product during pregnancy and lactation is not recommended.

Fertility:

The safety of dexmedetomidine has not been established in males intended for breeding.

Interaction with other medicinal products and other forms of interaction:

The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made. Anticholinergics should be used with caution with dexmedetomidine.

Administration of atipamezole after dexmedetomidine rapidly reverses the effects and thus shortens the recovery period. Within 15 minutes dogs and cats are normally awake and standing.

Cats: After administration of 40 micrograms dexmedetomidine/kg bw intramuscularly concurrently with 5 mg ketamine/kg bw to cats, the maximum concentration of dexmedetomidine increased twofold but there was no effect on Tmax. The mean half-life of elimination of dexmedetomidine increased to 1.6 h and the total exposure (AUC) increased by 50%.

A dose of 10 mg ketamine/kg used concurrently with 40 micrograms dexmedetomidine/kg may cause tachycardia.

Overdose:

Dogs:

In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area). The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of the veterinary medicinal product that was given to the dog, regardless of route of administration of the veterinary medicinal product.

Cats:

In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose dexmedetomidine in micrograms/kg bw.

After concurrent exposure to a triple (3X) overdose of dexmedetomidine and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine. At high serum concentrations of dexmedetomidine sedation is not increased although the level of analgesia does increase with further dose increases. The dose volume of atipamezole at the concentration of 5 mg/ml equals one-half the volume of the veterinary medicinal product that was given to the cat.

[Special restrictions for use and special conditions for use:]

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products, with the following exception: Dexmedetomidine is compatible with butorphanol and ketamine in the same syringe at least for two hours.

7. Adverse events

Dogs:

Very common (> 1 animal / 10 animals treated):	Bradycardia (slow heart rate) ^{1,5} Cyanotic mucous membranes (blue appearance of) ² , Pale mucous membranes ²
Common (1 to 10 animals / 100 animals treated):	Arrhythmia (irregular heartbeat) ^{6,8,9}
Rare (1 to 10 animals / 10 000 animals treated):	Pulmonary oedema (fluid accumulation in the lungs)
Undetermined frequency (cannot be estimated from the available data):	Excitation ¹ Heart block ¹ , Premature ventricular contractions ¹ , High blood pressure ³ , Low blood pressure ³ , Hypersalivation (increased salivation) ¹ , Retching ¹ , Vomiting ^{1,4} Muscle tremor ¹ , Twitching ¹ , Paddling ¹ , Sedation prolonged ¹ Bradypnoea (slow breathing rate) ^{1,5} , Tachypnoea (rapid breathing) ^{1,5} , Irregular breathing ^{1,7} , Decreased pulse oxygenation ¹ , Erythema (redness) ¹ Decreased body temperature Urination ¹

¹ When dexmedetomidine and butorphanol are used concomitantly.

² Due to peripheral vasoconstriction and venous desaturation in the presence of normal arterial oxygenation.

³ Blood pressure will increase initially and then return to normal or below normal.

⁴ May occur 5–10 minutes after injection. Some dogs may also vomit at the time of recovery.

⁵ When dexmedetomidine is used as a premedicant.

⁶ When dexmedetomidine and butorphanol are used concomitantly in dogs, brady- and tachyarrhythmias have been reported. These may include profound sinus bradycardia, 1st and 2nd degree AV block, sinus arrest or pause, as well as atrial, supraventricular and ventricular premature complexes.

⁷ 20-30 sec apnea followed by rapid breaths.

⁸ When dexmedetomidine is used as a premedicant brady- and tachyarrhythmias have been reported and include profound sinus bradycardia, 1st and 2nd degree AV block and sinus arrest. Supraventricular and ventricular premature complexes, sinus pause, and 3rd degree AV block may be observed in rare cases.

⁹ Supraventricular and nodal arrhythmia when dexmedetomidine and butorphanol are used concomitantly.

Cats:

Very common (> 1 animal / 10 animals treated):	Bradycardia (slow heart rate) ¹ , Arrhythmia (irregular heartbeat) ⁶ Heart block ^{1,2} Vomiting ^{1,2,3} Pale mucous membranes ^{1,4} , Cyanotic mucous membranes (blue appearance of) ⁴
Common (1 to 10 animals / 100 animals treated):	Retching ¹ Decreased pulse oxygenation ^{2,7} Hypothermia ²
Uncommon (1 to 10 animals / 1 000 animals treated):	Apnoea ²
Rare (1 to 10 animals / 10 000 animals treated):	Pulmonary oedema (fluid accumulation in the lungs)
Undetermined frequency (cannot be estimated from the available data):	Extrasystole ² , High blood pressure ⁵ , Low blood pressure ⁵ Corneal opacity (clouding of the eye) Muscle tremor, Decreased body temperature ¹ Bradypnoea (slow breathing rate) ² , Decreased respiratory rate, Hypoventilation ² , Irregular breathing ² Agitation ²

¹ When dexmedetomidine is used as a premedicant.

² When dexmedetomidine and ketamine are used sequentially.

³ May occur 5–10 minutes after injection. Some cats may also vomit at the time of recovery.

⁴ Due to peripheral vasoconstriction and venous desaturation in the presence of normal arterial oxygenation.

⁵ Blood pressure will increase initially and then return to normal or below normal.

⁶ Intramuscular dosing at 40 micrograms/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.

⁷ Especially within the 15 first minutes into dexmedetomidine-ketamine anesthesia.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation

holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

8. Dosage for each species, routes and method of administration

- Dogs: intravenous (IV) or intramuscular (IM) use.
- Cats: intramuscular (IM) use.

The veterinary medicinal product is not intended for repeated injections.

Dosage: the following doses are recommended:

Dogs:

Dexmedetomidine doses are based on body surface area:

Intravenously: up to 375 micrograms/square metre body surface area

Intramuscularly: up to 500 micrograms/square metre body surface area

When administering in conjunction with butorphanol (0.1 mg/kg bw) for deep sedation and analgesia, the intramuscular dose of dexmedetomidine is 300 micrograms/square metre body surface area. The premedication dose of dexmedetomidine is 125 – 375 micrograms/square metre body surface area, administered 20 minutes prior to induction for procedures requiring anaesthesia. The dose should be adjusted to the type of surgery, length of procedure and patient temperament.

Concomitant use of dexmedetomidine and butorphanol produces sedative and analgesic effects beginning no later than 15 minutes. The peak sedative and analgesic effects are reached within 30 minutes after administration. Sedation lasts for at least 120 minutes post administration and analgesia lasts for at least 90 minutes. Spontaneous recovery occurs within 3 hours.

Premedication with dexmedetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. In a clinical study, the requirement for propofol and thiopental was reduced by 30% and 60% respectively. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect. In a clinical study, dexmedetomidine contributed to postoperative analgesia for 0.5 – 4 hours. However, this duration is dependent on a number of variables and further analgesia should be administered in accordance with clinical judgement.

The corresponding doses based on body weight are presented in the following tables. Use of an appropriately graduated syringe is recommended to ensure accurate dosing when administering small volumes.

Dog Weight (kg)	Dexmedetomidine 125 mcg/m² (mcg/kg bw)	Dexmedetomidine 375 mcg/m² (mcg/kg bw)	Dexmedetomidine 500 mcg/m² (mcg/kg bw)
2-3	9.4	0.04	28.1
3-4	8.3	0.05	25
4-5	7.7	0.07	23
5-10	6.5	0.1	19.6
10-13	5.6	0.13	16.8
13-15	5.2	0.15	15.7
15-20	4.9	0.17	14.6
20-25	4.5	0.2	13.4
25-30	4.2	0.23	12.6
30-33	4	0.25	12

33-37	3.9	0.27	11.6	0.81	15	1.1
37-45	3.7	0.3	11	0.9	14.5	1.2
45-50	3.5	0.33	10.5	0.99	14	1.3
50-55	3.4	0.35	10.1	1.06	13.5	1.4
55-60	3.3	0.38	9.8	1.13	13	1.5
60-65	3.2	0.4	9.5	1.19	12.8	1.6
65-70	3.1	0.42	9.3	1.26	12.5	1.7
70-80	3	0.45	9	1.35	12.3	1.8
>80	2.9	0.47	8.7	1.42	12	1.9

For deep sedation and analgesia with butorphanol

Dog Weight (kg)	Dexmedetomidine 300 mcg/m ² intramuscularly (mcg/kg bw)	(ml)
2-3	24	0.12
3-4	23	0.16
4-5	22.2	0.2
5-10	16.7	0.25
10-13	13	0.3
13-15	12.5	0.35
15-20	11.4	0.4
20-25	11.1	0.5
25-30	10	0.55
30-33	9.5	0.6
33-37	9.3	0.65
37-45	8.5	0.7
45-50	8.4	0.8
50-55	8.1	0.85
55-60	7.8	0.9
60-65	7.6	0.95
65-70	7.4	1
70-80	7.3	1.1
>80	7	1.2

Cats:

The dosage for cats is 40 mcg dexmedetomidine hydrochloride/kg bw equal to a dose volume 0.08 ml of the veterinary medicinal product/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.

When dexmedetomidine is used for premedication in cats, the same dose is used. Premedication with dexmedetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. In a clinical study, the requirement for propofol was reduced by 50%. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect.

Anaesthesia can be induced 10 minutes after premedication by intramuscular administration of a target dose of 5 mg ketamine/ kg bw or by intravenous administration of propofol to effect. Dosing for cats is presented in the following table.

Cat Weight (kg)	Dexmedetomidine 40 mcg/kg intramuscularly (mcg/kg bw)	(ml)
1-2	40	0.1
2-3	40	0.2
3-4	40	0.3
4-6	40	0.4
6-7	40	0.5

7-8	40	0.6
8-10	40	0.7

The expected sedative and analgesic effects are reached within 15 minutes after administration and are maintained up to 60 minutes after administration. Sedation may be reversed with atipamezole. Atipamezole should not be administered prior to 30 minutes following ketamine administration.

9. Advice on correct administration

It is recommended that animals are fasted for 12 hours prior to the veterinary medicinal product administration. Water may be given.

After treatment, the animal should not be given water or food before it is able to swallow.

This veterinary medicinal product is compatible with butorphanol and ketamine in the same syringe at least for two hours.

The stopper must not be punctured more than 25 times.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorization numbers and pack sizes

Marketing authorisation number:
Pack sizes: cardboard box with 1 vial of 10 ml.

15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder:

Vetpharma Animal Health, S.L.
Gran Via Carles III, 98, 7^a
08028 Barcelona
Spain

Manufacturer responsible for batch release:

CHEMICAL IBÉRICA PV, S.L.
Ctra. Burgos-Portugal, Km. 256
Calzada de Don Diego, 37448 Salamanca
Spain

Local representatives and contact details to report suspected adverse reactions:

17. Other information